Halting the Epidemic of Addiction and Loss Act of 2025
Sponsored By: Senator Cornyn, John [R-TX]
Introduced
Summary
Makes HHS grant rules explicitly cover any FDA-approved opioid overdose reversal drug. It would require the HHS Secretary to update existing regulations and guidance within one year after enactment so any reference to an "opioid overdose reversal drug" in the State and Tribal Opioid Response grants (section 1003 of the 21st Century Cures Act) and the priority prevention grants (section 516 of the Public Health Service Act) includes any drug approved or authorized by the Food and Drug Administration under section 505 for emergency treatment of a known or suspected opioid overdose.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Broader language for overdose drugs
This bill would require HHS to make its rules and guidance cover any opioid overdose reversal drug the FDA approves or authorizes. An example is naloxone. If enacted, HHS would have to update rules or guidance issued before enactment within one year after enactment. The updates would include State and Tribal Opioid Response Grants and the Public Health Service Act section 516 grant program. HHS would also use the same inclusive language in future grant rules and guidance.
Sponsors & CoSponsors
Sponsor
Cornyn, John [R-TX]
TX • R
Cosponsors
Sen. Hassan, Margaret Wood [D-NH]
NH • D
Sponsored 7/17/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov